# SH2B3

Source: https://onco.cc/targets/sh2b3/  
OnCo record `sh2b3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SH2B3 (SH2B adapter protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Myeloproliferative neoplasms, Endometrial cancer and 4 more.

## Summary

Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.76, literature 0.96, genetic association 0.90, somatic mutation 0.88, animal model 0.75). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Myelodysplastic Syndromes.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: SH2B adaptor protein 3; SH2B adapter protein 3; IDDM20
- Tags: cancer-genes-wave
- Symbol: SH2B3
- Class: oncogene
- Biology: Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase. Locus 12q24.12 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.63 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Myeloproliferative neoplasms: Open Targets association 0.61 with myeloproliferative neoplasm (MONDO_0020076); Endometrial cancer: Open Targets association 0.59 with endometrial cancer (MONDO_0011962); Myelodysplastic syndromes / neoplasms: IntOGen driver in 1 cohort (MDS); Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059); Sarcomas: Open Targets association 0.54 with sarcoma (MONDO_0005089)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:29605: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29605
- UniProt Q9UQQ2: https://www.uniprot.org/uniprotkb/Q9UQQ2/entry
- NCBI Gene 10019: https://www.ncbi.nlm.nih.gov/gene/10019
- Ensembl ENSG00000111252: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111252

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/sh2b3.json